Skip to content

Author

L. Alinari

We have 3 of 221 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma

The prevalence of CAR-positive T cells in patient-derived tissue sections, observed metabolic and proliferative shifts in the tumor and its microenvironment, and immune checkpoint analysis provide insights into post-CAR T secondary cancers and highlight tools that may guide future targeted therapies.

Jia-Jye Lee, Peirong Hu, Kun Luo et al. · 0 citations
Jul 2026

Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

A trispecific CAR targeting CD19, CD20, and CD22 with OX40 co-stimulatory domain with overall response rate was 50%, including complete responses in 83% of lymphoma patients, and one-year overall survival rate was 61%, with durable remissions observed in lymphoma.

S. Vasu, N. Denlinger, No-Joon Song et al. · 0 citations
Open access Jul 2026

Decoding Histone-DNA Methylation Crosstalk in Exhausted T Cells to Enhance Immunotherapy 2253691

A central histone—DNA methylation circuit, regulated by KDM5A/B and DNMT3A, that drives epigenetic scarring and terminal exhaustion in CD8 T cells is uncovered and Therapeutic targeting of this circuit offers a novel approach to epigenetically reprogram TEX cells and enhance the efficacy of cancer immunotherapy.

Hazem E. Ghoneim, Amira Yousif, Abbey A. Saadey et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.